Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 132 results:
[ Συντάκτης] Τίτλος Τύπος Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need..
Curr Med Res Opin. 38(6), 885-888.
(2022). Helicobacter pylori Infection and insulin resistance..
Helicobacter. 18(2), 165-6.
(2013). Lipodystrophy: Time for a global registry and randomized clinical trials to assess efficacy, safety and cost-effectiveness of established and novel medications..
Metabolism. 72, A4-A10.
(2017). Thyroid nodules - stepwise diagnosis and management..
Hormones (Athens). 6(2), 101-19.
(2007). Selenium and selenoprotein P in nonalcoholic fatty liver disease..
Hormones (Athens). 19(1), 61-72.
(2020). A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy..
World J Surg. 34(4), 844-51.
(2010). Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease..
Curr Pharm Des. 29(41), 3263-3265.
(2023). Bone and fat interplay in inflammatory bowel disease: clinical implications and future perspectives..
Inflamm Bowel Dis. 20(11), E22.
(2014). Serum homocysteine, folate and vitamin B12 in patients with Paget's disease of bone: the effect of zoledronic acid..
J Bone Miner Metab. 28(3), 314-9.
(2010). Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited..
J Gastrointestin Liver Dis. 29(2), 270-271.
(2020). Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone..
Clin Rheumatol. 30(1), 149-50.
(2011). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis..
Hormones (Athens). 13(4), 519-31.
(2014). Cilofexor for the Treatment of Nonalcoholic Steatohepatitis.
Curr Vasc Pharmacol.
(2021). Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease..
Metabolism. 61(6), 755-8.
(2012). Homocysteine in nonalcoholic steatohepatitis: A reply..
Eur J Intern Med. 35, e40-e41.
(2016). Helicobacter pylori infection and nonalcoholic fatty liver disease: Time for large clinical trials evaluating eradication therapy..
Helicobacter. 24(3), e12588.
(2019). Histological alterations following thyroid fine needle biopsy: a systematic review..
Diagn Cytopathol. 37(6), 455-65.
(2009). Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy..
Semin Cancer Biol. 93, 20-35.
(2023). A novel noninvasive index for nonalcoholic steatohepatitis: a pilot study..
Biomarkers. 18(7), 607-13.
(2013). Outliers of bone metabolic diseases..
Metabolism. 80, 1-4.
(2018). Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity..
Hepatobiliary Surg Nutr. 9(1), 73-76.
(2020). Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Circulating homocysteine in nonalcoholic fatty liver disease..
Eur J Intern Med. 26(2), 152-3.
(2015). Coincidental thyroid papillary microcarcinoma in a patient treated for a toxic adenoma of the thyroid..
Arch Iran Med. 14(2), 149-51.
(2011).